A Highly Potent Human Antibody Neutralizing All Serotypes of BK Polyomavirus

A Highly Potent Human Antibody Neutralizing All Serotypes of BK Polyomavirus | bioRxiv /* */ /* */ <!-- <!-- /*! * yepnope1.5.4 * (c) WTFPL, GPLv2 */ (function(a,b,c){function d(a){return"[object Function]"==o.call(a)}function e(a){return"string"==typeof a}function f(){}function g(a){return!a||"loaded"==a||"complete"==a||"uninitialized"==a}function h(){var a=p.shift();q=1,a?a.t?m(function(){("c"==a.t?B.injectCss:B.injectJs)(a.s,0,a.a,a.x,a.e,1)},0):(a(),h()):q=0}function i(a,c,d,e,f,i,j){function k(b){if(!o&&g(l.readyState)&&(u.r=o=1,!q&&h(),l.onload=l.onreadystatechange=null,b)){"img"!=a&&m(function(){t.removeChild(l)},50);for(var d in y[c])y[c].hasOwnProperty(d)&&y[c][d].onload()}}var j=j||B.errorTimeout,l=b.createElement(a),o=0,r=0,u={t:d,s:c,e:f,a:i,x:j};1===y[c]&&(r=1,y[c]=[]),"object"==a?l.data=c:(l.src=c,l.type=a),l.width=l.height="0",l.onerror=l.onload=l.onreadystatechange=function(){k.call(this,r)},p.splice(e,0,u),"img"!=a&&(r||2===y[c]?(t.insertBefore(l,s?null:n),m(k,j)):y[c].push(l))}function j(a,b,c,d,f){return q=0,b=b||"j",e(a)?i("c"==b?v:u,a,b,this.i++,c,d,f):(p.splice(this.i++,0,a),1==p.length&&h()),this}function k(){var a=B;return a.loader={load:j,i:0},a}var l=b.documentElement,m=a.setTimeout,n=b.getElementsByTagName("script")[0],o={}.toString,p=[],q=0,r="MozAppearance"in l.style,s=r&&!!b.createRange().compareNode,t=s?l:n.parentNode,l=a.opera&&"[object Opera]"==o.call(a.opera),l=!!b.attachEvent&&!l,u=r?"object":l?"script":"img",v=l?"script":u,w=Array.isArray||function(a){return"[object Array]"==o.call(a)},x=[],y={},z={timeout:function(a,b){return b.length&&(a.timeout=b[0]),a}},A,B;B=function(a){function b(a){var a=a.split("!"),b=x.length,c=a.pop(),d=a.length,c={url:c,origUrl:c,prefixes:a},e,f,g;for(f=0;f<d;f++)g=a[f].split("="),(e=z[g.shift()])&&(c=e(c,g));for(f=0;f<b;f++)c=x[f](c);return c}function g(a,e,f,g,h){var i=b(a),j=i.autoCallback;i.url.split(".").pop().split("?").shift(),i.bypass||(e&&(e=d(e)?e:e[a]||e[g]||e[a.split("/").pop().split("?")[0]]),i.instead?i.instead(a,e,f,g,h):(y[i.url]?i.noexec=!0:y[i.url]=1,f.load(i.url,i.forceCSS||!i.forceJS&&"css"==i.url.split(".").pop().split("?").shift()?"c":c,i.noexec,i.attrs,i.timeout),(d(e)||d(j))&&f.load(function(){k(),e&&e(i.origUrl,h,g),j&&j(i.origUrl,h,g),y[i.url]=2})))}function h(a,b){function c(a,c){if(a){if(e(a))c||(j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}),g(a,j,b,0,h);else if(Object(a)===a)for(n in m=function(){var b=0,c;for(c in a)a.hasOwnProperty(c)&&b++;return b}(),a)a.hasOwnProperty(n)&&(!c&&!--m&&(d(j)?j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}:j[n]=function(a){return function(){var b=[].slice.call(arguments);a&&a.apply(this,b),l()}}(k[n])),g(a[n],j,b,n,h))}else!c&&l()}var h=!!a.test,i=a.load||a.both,j=a.callback||f,k=j,l=a.complete||f,m,n;c(h?a.yep:a.nope,!!i),i&&c(i)}var i,j,l=this.yepnope.loader;if(e(a))g(a,0,l,0);else if(w(a))for(i=0;i (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0];var j=d.createElement(s);var dl=l!='dataLayer'?'&l='+l:'';j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;j.type='text/javascript';j.async=true;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-M677548'); Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search New Results A Highly Potent Human Antibody Neutralizing All Serotypes of BK Polyomavirus Marcel Weber , Simone Schmitt , Barbara Eicher , Jemima Seidenberg , Justina Rutkauskaite , Catherine Townsend , Uyen Huynh-Do , Thomas Schachtner , Serena Delbue , Armin Mäder , View ORCID Profile Christoph Esslinger , Matthias Hillenbrand doi: https://doi.org/10.1101/2025.04.14.648680 Marcel Weber 1 Memo Therapeutics AG , Schlieren Zurich, Switzerland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Simone Schmitt 1 Memo Therapeutics AG , Schlieren Zurich, Switzerland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Barbara Eicher 1 Memo Therapeutics AG , Schlieren Zurich, Switzerland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jemima Seidenberg 1 Memo Therapeutics AG , Schlieren Zurich, Switzerland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Justina Rutkauskaite 1 Memo Therapeutics AG , Schlieren Zurich, Switzerland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Catherine Townsend 1 Memo Therapeutics AG , Schlieren Zurich, Switzerland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Uyen Huynh-Do 2 Division of Nephrology and Hypertension, University Hospital Bern , Switzerland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Thomas Schachtner 3 Division of Nephrology, University Hospital Zurich , Zürich, Switzerland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Serena Delbue 4 Department of Biomedical, Surgical and Dental Sciences, University of Milan , Italy Find this author on Google Scholar Find this author on PubMed Search for this author on this site Armin Mäder 1 Memo Therapeutics AG , Schlieren Zurich, Switzerland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christoph Esslinger 1 Memo Therapeutics AG , Schlieren Zurich, Switzerland Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Christoph Esslinger Matthias Hillenbrand 1 Memo Therapeutics AG , Schlieren Zurich, Switzerland Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: matthias.hillenbrand{at}memo-therapeutics.com Abstract Full Text Info/History Metrics Preview PDF Abstract BK polyomavirus infection poses a significant risk to kidney transplant recipients. Reactivation of dormant virus in the transplanted kidney, triggered by immunosuppression, can lead to BK polyomavirus-associated nephropathy in up to 10% of transplants, often resulting in loss of graft function or even graft loss. Currently, there is no specific treatment that reliably prevents BK polyomavirus-associated nephropathy or halts its progression. Standard of care relies on reducing immunosuppression, allowing the immune system to gradually control the infection but at the risk of provoking rejection episodes and compromising kidney function. This study describes the discovery and characterization of an ultra-potent BK polyomavirus-neutralizing antibody, identified from a kidney transplant recipient who displayed rapid clearance of high-level BK viremia. Antibody mAb 319C07 (USAN potravitug) neutralizes all four BK polyomavirus serotypes and recognizes an epitope critical for viral cell attachment. mAb 319C07 is in clinical development for the treatment of BKPyV infection in renal transplant patients ( NCT05769582 ). Introduction BK polyomavirus (BKPyV) is a non-enveloped polyomavirus with a double-stranded, circular DNA genome of approximately 5,000 base pairs [ 1 ]. Its major capsid protein, VP1, forms a protein capsid comprising 72 VP1 pentamers in which other viral proteins, VP2 and VP3, are incorporated. VP1 is the only protein exposed at the outer surface of the capsid. Four major serotypes (I, II, III, and IV) of BKPyV VP1 are distinguished, each engaging gangliosides in the cell membrane for cell entry [ 1 , 2 ]. Target cells are renal tubular epithelial cells and podocytes (REF missing) BKPyV infection usually occurs during childhood and remains latent in renal tubular cells and the urothelium typically with no or minimal clinical consequence [ 3 ]. It is estimated that up to 90% of the adult population is infected [ 4 ]). In kidney transplant recipients, immunosuppression frequently reactivates latent BKPyV, usually in the transplanted kidney [ 5 , 6 ]. Up to 40% of kidney transplant recipients experience BKPyV reactivation [ 6 ], and up to 10% develop BK polyomavirus-associated nephropathy (BKPyV-nephropathy) [ 6 – 8 ]. BKPyV-nephropathy can severely impact graft function and graft longevity, potentially leading to graft failure [ 6 , 9 ]. Currently, the standard of care — reducing immunosuppressive therapy — carries a substantial risk of acute or chronic graft rejection [ 6 ] [ 10 ] [ 11 ] [ 12 ]. Investigations into antiviral agents such as cidofovir, leflunomide, and quinolones have produced inconclusive data regarding potential benefits [ 6 ]. Adoptive transfer of virus-specific allogeneic T cells has also shown only limited efficacy, with modest reductions in BKPyV viremia [ 13 ]. The role of humoral immunity in preventing BKPyV infection has long been a matter of debate in numerous small clinical studies, and intravenous immunoglobulins have historically served as a last-resort option, albeit with limited, or only indirect evidence of benefit [ 6 ] [ 14 ] [ 15 ]. More recent studies, however, may suggest a protective effect of antibodies. Fafi-Kremer and colleagues describe that pre-existing neutralizing antibody titers correlated with reduced BKPyV viremia post-transplant. Furthermore, they observed that rising neutralizing antibody titers in patients with viruria, viremia, or BKPyV nephropathy coincided with declining viral loads in urine and/or blood [ 16 ]. Additionally, a candidate therapeutic monoclonal antibody, MAU868, demonstrated moderate efficacy in a phase II study. After 16 weeks of treatment, BKPyV viremia was reduced by at least 1 log in 40% of patients, with 20% achieving undetectable virus levels, compared to 0% in the placebo group [ 17 ]. These findings suggest that antibodies could be a viable approach to reduce viral load and potentially prevent progression to BKPyV-nephropathy. Leveraging our powerful antibody discovery platform DROPZYLLA®, previously used for fast-track discovery of SARS-CoV-2-neutralizing antibodies [ 18 ], we comprehensively assessed the BKPyV-neutralizing antibody repertoires in healthy donors and kidney transplant recipients, who clinically demonstrated fast viral clearance. Using this approach, we identified nine antibodies with equal or superior properties to a benchmark BKPyV-neutralizing antibody containing the Fab-region of the human-derived antibody P8D11. One candidate, mAb 319C07, with ultra-potent activity against all BKPyV-serotypes and occupying a key epitope on VP1 required for cell entry, was selected. mAb 319C07 (aliases AntiBKV, potravitug) is currently under clinical development for the treatment of BKPyV infection in renal transplant patients (US FDA Fast Track, NCT05769582 ) [ 19 ]. Results Antibody discovery strategy We recruited over forty healthy donors and over thirty kidney transplant recipients (KTR) to maximize the diversity of BK polyomavirus-specific immune responses ( Figure 1 ). Healthy donors were selected based on the presence of measurable neutralizing antibody titers, whereas KTR participants were additionally required to demonstrate rapid viral clearance. Download figure Open in new tab Figure 1. Antibody discovery was performed using the DROPZYLLA platform, which allows for the cloning and preservation of cognate heavy and light chain pairing of single B cells. Antibody repertoire libraries were expressed as membrane IgG in mammalian cells and cells that bound BKPyV VP1 pentamer were isolated using antigen-specific sorting. Antibody specificity was confirmed semi quantitatively using soluble IgG, followed by cell-based neutralization and cross-reactivity testing against the four BKPyV serotypes. The neutralization potency of pan-serotype neutralizing antibodies was then compared to the benchmark antibody P8D11, and a development candidate, mAb 319C07 was selected based on neutralization efficacy and developability. Antibody discovery employed Memo Therapeutics’ DROPZYLLA® platform [ 18 ], which integrates droplet microfluidics to capture antibody genes from up to one million single human peripheral blood memory B cells (typically up to 200,000 memory B cells were obtained per sample). Cognate heavy- and light-chain variable regions remain linked, yielding expression libraries of full-length, membrane-bound IgG which were expressed in HEK293T cells. We screened these libraries via fluorescence-activated cell sorting (FACS) using fluorescently labeled pentameric VP1 capsid protein ( Figure 1 ). Subsequent selection steps included binding studies against VP1 of all four BKPyV serotypes and cell-based neutralization assays utilizing a well-established pseudovirus system (Pastrana/Buck). This approach identified twenty-nine antibodies demonstrating strong neutralization across all BKPyV-serotypes. To identify the lead candidate, we benchmarked these 29 antibodies against mAb P8D11, a human-derived antibody with picomolar affinity and potent neutralization activity [ 20 ]. Nine antibodies—7 derived from kidney transplant recipients—were prioritized and evaluated for developability, including expression efficiency, stability, purity, and sequence liabilities. Based on neutralization potency across all serotypes and favorable developability profiles, mAb 319C07 was selected as the lead candidate. mAb 319C07 is a human IgG1/kappa antibody isolated from a cognate memory B cell repertoire library obtained from peripheral blood of a kidney transplant recipient who exhibited rapidly increasing viremia at 5 months post-transplant, surpassing the threshold of 10,000 IU/mL within two weeks of initial detection. In response, immunosuppressive therapy was adjusted by reducing doses of both the antiproliferative agent and the calcineurin inhibitor. Subsequently, the viral load continued to rise, peaking at 190,000 IU/mL less than one month later, but then sharply decreased to 90,000 IU/mL within the following five days. It was at this critical juncture that the blood sample was collected for antibody repertoire analysis. Following sample collection, the viral load further declined, eventually becoming undetectable around nine months after reaching peak viremia. mAb 319C07 binds to all major serotypes of BKPyV with picomolar affinity Binding of mAb 317C09 to BKPyV VP1 serotypes I, II, III and IV was analyzed by ELISA and showed picomolar affinity of mAb 319C07 to all four serotypes ( Figure 2 , Table 1 ). Benchmark antibody mAb P8D11 showed similar affinity for serotype III, but slightly decreased affinity for serotypes I, II an IV. mAb 24C03, an antibody directed against tetanus toxoid, was used as a negative control and did not show binding to VP1. View this table: View inline View popup Download powerpoint Table 1. Summary of EC50 values (in nM) determined by ELISA. Download figure Open in new tab Figure 2. Binding of mAb 319C07, mAb P8D11 and mAb 24C03 (negative control) to BKPyV VP1-Ib1, II, III or IV assessed by ELISA. The mean of triplicate wells ± SD from a representative experiment was plotted, and nonlinear sigmoidal dose-response regression was used to fit the curves for each mAb. EC50 values for mAb319C07 and mAb P8D11 are shown in Table 1 . Inhibition of BKPyV-VP1 binding to target cells by mAb 319C07 We investigated whether mAb 319C07 could block the binding of BKPyV VP1 to host cells. In a flow cytometry assay using HEK293TT cells as target, VP1 pentamer attachment to cells was measured in the presence of increasing antibody concentrations. mAb 319C07 and mAb P8D11 showed a dose-dependent inhibition of cell attachment for all VP1 serotypes, although mAb P8D11 required higher concentrations to show this effect ( Figure 3 and S1, Table 2 and S1 ). These results suggest that the neutralizing effect of both antibodies is likely mediated via blockade of viral attachment to cells. Control antibody mAb 24C03 did not show any effect on VP1 binding. View this table: View inline View popup Table 2. Percent binding of BK VP1 serotype Ib1 to HEK293TT cells in the presence or absence of antibodies. Median fluorescent intensity of plots shown in Figure 3 were extracted using FlowJo 10.7.1 and normalized to 100% VP1 binding (VP1-Ib1 binding to HEK293TT cells in the absence of antibodies) and 0 % VP1 binding (HEK293TT cells with detection antibody only). For mAb 319C07 and mAb P8D11 a concentration-dependent decrease in VP1 binding to the cells was observed. mAb 24C03 does not inhibit VP1 binding to HEK293TT cells. n=1, 15000 cells analyzed per concentration. Download figure Open in new tab Figure 3. Inhibition of binding of BKPyV VP1 to HEK293TT cells in the presence of mAb 319C07. Attachment of VP1 serotype I pentamer to HEK293TT cells in the absence (dark green) or presence of antibody (mAb319C07, mAb P8D11 or mAb 24C03) at different concentrations (shades of blue) was analyzed. VP1 binding to HEK293TT cells was detected using an AF488 labelled anti-VP1 antibody and compared to cells with detection antibody only (black). Analysis was done by analytic flow cytometry. A shift of the HEK293TT population to higher signals (right-shift) over background (black) indicates binding of VP1 to the cells. Neutralization of All BKPyV Serotypes by mAb 319C07 To determine the neutralization potency of mAb 319C07, a cell-based pseudovirus assay was employed. The pseudoviruses comprised BKPyV structural proteins VP1, VP2, and VP3, packaging a luciferase reporter gene as payload. These virus-like particles authentically mimic BKPyV capsid structure and immunogenic properties, enabling accurate quantification of infection via luciferase activity. In these assays, antibody mAb 319C07 exhibited robust neutralization across all four major BKPyV serotypes (I–IV) and significantly outperformed benchmark antibody mAb P8D11 against serotypes I, II, and IV ( Figure 4 ), which together account for over 98% of global BKPyV infections [ 21 ]. Download figure Open in new tab Figure 4. Neutralisation of BK polyoma (BKPy) pseudovirus serotype I, II, III and IV by mAb 319C07 and mAb P8D11. Control mAb 24C03 is directed against tetanus toxoid and does not show neutralization of BKPyV. The mean of triplicate wells ± SD (except mAb 24C03 which was done in duplicate only) from a representative experiment was plotted, and nonlinear sigmoidal dose-response regression was used to fit the curves for each mAb. IC50 values for mAb319C07 anf mAb P8D11 are shown in Table 3 . Representative IC50 values of mAb 319C07-neutralization are also summarized in the Table 3 . View this table: View inline View popup Download powerpoint Table 3. In vitro neutralizing activity of mAb 319C07 and mAb P8D11 against the 4 major BKPyV serotypes. Neutralization activity was determined in HEK293TT cells by measuring luciferase expression 72 hours after infection with pseudoviruses. Data are expressed as the median IC50 ± SD from 3 (serotypes I, II, and III) or 10 (serotype IV) independent experiments. We next compared the neutralization potency of mAb 319C07 to that of a commercially available immunoglobulin preparation. Immunoglobulin preparations are commonly administered as an adjuvant therapy in kidney transplant recipients exhibiting insufficient viral clearance following immunosuppression reduction. Our findings demonstrate that the neutralization potency of the immunoglobulin preparation is approximately four logs lower than that of mAb 319C07 ( Figure 5 ). Considering typical administered doses—immunoglobulin at 20–140 g per injection versus and potravitug (mAb 319C07) at 1 g per injection—mAb 319C07 is estimated to provide approximately 100–500-fold greater neutralizing capacity compared to the immunoglobulin. BKPyV VP1 epitope determination for antibody mAb 319C07 For epitope determination, protein crystallography was used to solve the structure of mAb 319C07 bound to BKPyV VP1 Ib1 pentamer at a resolution of 1.96 Å. Crystal structure analysis revealed that 319C07 Fab binds to the capsid outside-facing surface of the VP1 pentamer, with one Fab fragment bridging two adjacent monomers ( Figure 5 ). Both heavy- and light-chain complementarity-determining regions (CDRs) participate in the interaction. The epitope on VP1 is localized to two distinct regions: the hypervariable BC-loop and a highly conserved region also involved in BKPyV receptor interaction. Notably, the CDR3 of the heavy chain interacts with VP1 residues shown to be key for receptor interaction [ 22 ], more specifically to amino acid residues K69, F76, N273, S274, S275, and T277. Thus, mAb 319C07 efficiently blocks the binding of VP1 to its cellular receptor, preventing virus cell entry and rendering viral escape by mutation highly unlikely. Download figure Open in new tab Figure 5. Comparative analysis neutralisation potency of monoclonal antibodies 319C07, P8D11 and an immunoglobulin preparation (Hizentra). Serial dilutions of antibodies were tested in a cell-based infection assay using BKPyV serotype I pseudovirus. The mean values of triplicate wells ± SD from a representative experiment was plotted, and nonlinear sigmoidal dose-response regression was used to fit the curves for each mAb. Download figure Open in new tab Figure 5a. BKPyV-VP1 pentamer (powder blue) in complex with 5 Fab fragments of mAb 319C07 (dark blue and cyan), top and side view. Download figure Open in new tab Figure 7. Long term culture of replication competent BKPyV in the presence of antibody mAb 319C07 and subsequent analysis of putative VP1 sequence alterations. A) Neutralization capacity of mAb 319C07 and reference antibody mAb P8D11 plus negative control mAb 24C03 on HRPTEC infected with BKPyV serotype I was quantified. With antibodies mAb 319C07 and reference antibody mAb P8D11 assessment was performed in duplicate at all concentrations, for mAb 24C03, the highest concentration was used. Plotted are mean and ranges of n=2. B) Sequence analysis performed with the 3rd infection passage showed no occurrence of mutated virus. The epitope recognized by mAB 319C07 differs from those reported for other BKPyV-neutralizing antibodies, such as MAU868 [ 23 ] and 41F17 [ 24 ]. Both antibodies were identified through screens for binding to virus-like particles. The MAU868 scFv binds exclusively to a single VP1 monomer within the pentamer, while the 41F17 scFv interacts with three VP1 monomers spanning two adjacent pentamers. In contrast, neither antibody targets the highly conserved amino acid stretch N273–T277, which is bound by mAb 319C07 and essential for receptor binding and subsequent viral entry into host cells Resistance Profiling in Long-Term Culture The neutralization capacity of mAb 319C07 against BK virus serotypes I and IV, as well as the potential emergence of viral escape mutants, was assessed using primary human renal proximal tubular epithelial cells (HRPTEC) infected with replication-competent virus [ 24 ]. HRPTEC seeded in 96-well plates were incubated with mixtures of BK virus and antibody. After one week of culture, a portion of the supernatant was harvested for viral quantification by qPCR, while cells in the remaining supernatant underwent freeze-thaw cycles to release virus. For the subsequent cycle, virus containing lysate was added to a fresh HRPTEC-antibody co-culture. This procedure was repeated every two weeks for up to six cycles. Viral copy number was quantified by qPCR and viral DNA, extracted from lysed cells after the final passage was used for genotyping by sequencing of the VP1 region. Quantitative PCR confirmed a concentration-dependent reduction in viral load, with mAb 319C07 demonstrating superior neutralizing activity relative to the benchmark mAb P8D11. No escape mutants emerged in this assay, as confirmed by sequence analysis of the VP1 region showing consensus amino acid sequence of VP1. These results were reproduced for both serotype I and serotype IV in independent experiments (data not shown). Discussion BK polyomavirus (BKPyV) infection represents a critical and unmet medical need among kidney transplant recipients, significantly contributing to graft dysfunction and loss (Bennett et al. 2012; Ramos et al. 2009). The current standard of care is primarily centered on the reduction of immunosuppression. This, in turn, is associated with a substantial risks of graft rejection and compromised kidney function and kidney longevity [ 6 , 8 ]. Consequently, targeted antiviral therapy remains a high unmet medical need. Here, we present the characterization of mAb 319C07 (AntiBKV, potravitug), a novel human monoclonal antibody exhibiting ultra-potent neutralization across all BKPyV serotypes which is currently in clinical development for the treatment of BKPyV infection in kidney transplant recipients ( NCT05769582 ). The therapeutic potential of neutralizing antibodies against BKPyV has recently been underscored in clinical studies studying the pre-existing BKPyV-neutralizing antibody titers or aiming at complementing lacking neutralizing titers with the administration of immunoglobulin preparations or a monoclonal antibody. Fafi-Kremer and colleagues reported that pre-existing neutralizing antibody titers exceeding a defined threshold were associated with reduced BK viremia following transplantation[ 16 ]. In a subsequent clinical study by the same group, prophylactic administration of immunoglobulin preparations to patients with baseline neutralizing antibody titers below this protective threshold led to a decrease in viremia levels comparable to those observed in patients who initially exhibited high neutralizing antibody titers at transplantation[ 25 ]. However, this study was limited by a small sample size (n=3) in the immunoglobulin-treated group. Moreover, in a recent phase II clinical trial in kidney transplant recipients infected by BKPyV, the therapeutic monoclonal antibody MAU868 resulted in a more rapid and more pronounced reduction of viremia compared to placebo, where the intervention consisted solely of reducing immunosuppressive therapy. After 16 weeks of treatment, BKPyV viremia decreased by at least 1 log in 40% of patients, with 20% achieving undetectable viral levels, compared to 0% in the placebo group [ 17 , 26 ]. These findings indicate that antibody-based therapies could represent a promising approach to reduce viral loads and potentially prevent progression to BK polyomavirus-associated nephropathy (BKPyV nephropathy). In this context, antibody 319C07, which demonstrated substantially greater potency compared to mAb P8D11 (which shares an identical Fab sequence with MAU868) and conventional immunoglobulin preparations, may result in enhanced clinical efficacy. Mechanistically, antibody 319C07 robustly inhibited BK VP1 attachment to host cells, indicating that blocking initial viral attachment is its primary antiviral mechanism. Structural crystallographic analyses further support this by identifying an epitope located at the interface between two VP1 monomers, where the antibody’s CDR3H loop extends directly into receptor-binding sites on the viral capsid. This interaction likely prevents viral attachment, underpinning the potent antiviral activity observed in neutralization experiments. Targeting such a critical epitope may increase the potential for viral escape, a well-documented concern in antiviral therapies. Nevertheless, the joining site between VP1 monomers is highly conserved, and mutations in this region to avoid binding of mAb 319C07 would likely disrupt capsid formation, significantly compromising viral fitness. Although the clinical relevance of these observations will require confirmation through clinical studies, our long-term viral passaging experiments using primary human renal proximal tubular epithelial cells (HRPTEC) demonstrated sustained antiviral efficacy of mAb 319C07 without detectable emergence of escape mutants over multiple replication cycles. These findings suggest a low risk of viral escape with antibody 319C07, reducing concerns about diminished clinical efficacy during prolonged therapeutic use. The identification of mAb 319C07 from a kidney transplant recipient who exhibited rapid viral clearance may increase the chance for successful translation in the clinic. The efficient isolation and development of potent human antibodies from such donors using advanced platforms, such as DROPZYLLA®, could exemplify a novel paradigm for accelerated therapeutic antibody discovery tailored to highly specific medical challenges. Looking forward, the exceptional potency, broad serotype coverage, defined mechanism of action, and barrier to resistance may position antibody 319C07 as a transformative therapy for managing BKPyV infections in kidney transplant recipients. The ongoing clinical development (US FDA Fast Track, NCT05769582 ) will evaluate its potential to significantly alter current therapeutic approaches, potentially reducing or eliminating reliance on immunosuppression reduction. Material and methods Donors and Ethics Donor recruitment adhered to Swiss regulations (BASEC-2016-01260, Cantonal Ethics Commission of Zurich). Antibody Discovery Memory B cells, defined to be the cell population positive for CD22 and negative for CD3, CD8, CD56, IgA, IgD, and IgM, were isolated from peripheral blood and used to prepare cognate antibody repertoire expression libraries as described in patent WO2015121434. Briefly, single memory B cells were lysed in microfluidic droplets. Upon lysis, the mRNA was captured on mRNA capture beads, and after RT-PCR, single mRNA capture beads with attached cDNA were re-encapsulated in droplets and immunoglobulin heavy and light chain variable regions were amplified by droplet PCR [ 27 , 28 ]. PCR fragments of linked immunoglobulin light chain and heavy chain variable regions were cloned into an expression cassette, providing the human immunoglobulin constant heavy region combined with a transmembrane domain derived from human CD8 to allow for mammalian cell display of the antibodies. HEK293T cells displaying membrane-bound full-length IgG (mIgG-HEK) were generated by transduction of HEK293T cells with lentiviruses encoding the antibody repertoire. Screening of the antibody libraries was performed using flow cytometric sorting of antigen-specific cells using fluorescently labelled BKPyV-VP1. Single-cell-sorting yielded HEK cell clones expressing monoclonal antibodies with reactivity to VP1. Antibody-specificity was confirmed in analytical flow cytometry, testing for high-affinity binding of cell-membrane-expressed antibodies to purified VP1 protein. Production of Human Monoclonal Antibodies Selected antibodies were clones cloned into expression vectors for soluble IgG1 expression. Sequence information of the variable region of antibody P8D11 sequence was obtained from patent WO2017046676A1, ordered as a gene synthesis construct and cloned into IgG1 expression construct. Negative control/isotype control antibody (24C03) is a human-derived antibody specific for tetanus toxoid. The antibodies were expressed after transient transfection in HEK293F cells following the standard protocol as described by the manufacturer (ThermoFisher, Waltham, MA, USA). The antibodies were then purified from cell supernatant using Protein G High Performance Spintrap™ columns (GE Healthcare, Chicago, IL, USA) as recommended by the manufacturer. The purity and integrity of the proteins were checked by Coomassie stained SDS-PAGE (reducing and non-reducing) and SE-HPLC. Binding of monoclonal antibodies to BKPyV VP1 The binding of monoclonal antibodies to BKPyV VP1 serotypes Ib1, II, III and IV was analyzed by ELISA. Briefly, Costar® Assay Plate 96 well, half-area high binding plates were coated with 30 µl/well 1 µg/ml BKV VP1-Ib1, II, III or IV over weekend at 4 °C. Thereafter, plates were blocked for 1 hour using 5% skim milk powder diluted in PBS. After a wash step with PBS 0.05% Tween20, plates were incubated with 30 µl/well of diluted antibodies (in PBS with 0.5% skim milk powder) for 1 hour. Plates were washed with PBS 0.05% Tween20 and then incubated with secondary antibody (HRP-conjugated goat anti-human IgG) diluted 1:10’000 in PBS with 0.5% skim milk powder for 30 min. Plates were washed with PBS 0.05% Tween20. Reaction was developed using 30 µl/well TMB liquid substrate and development stopped after 2.5 min by addition of 15 µl/well 10 % H 2 SO 4 . Absorbance was detected at 450 nm. Data were fitted and apparent EC50 ELISA values determined using three-parameter analysis in GraphPad Prism 8. Inhibition of BKPyV-VP1 binding to target cells by monoclonal antibodies Antibodies under evaluation diluted to concentrations of 22.5 nM, 7.5 nM, 2.5 nM, 0.83 nM and 0.28 nM were incubated with VP1 serotype Ib1 pentamer (15.6 nM) or diluted to concentrations of 12 nM, 6 nM, 3 nM, 1.5 nM, 0.75 nM, 0.38 nM and 0.19 nM and incubated with VP1 pentamer serotype II (125.1 nM), serotype III (22.2 nM) or IV (7.8 nM) in binding buffer (PBS + 0.5% FBS) for 30 minutes at ambient temperature. VP1 pentamer concentrations were experimentally determined and are dependent on the affinity of the different serotypes to HEK293TT cells. HEK293TT cells were washed once in binding buffer and resuspended in antibody-VP1-mix or VP1 without antibody at 0.1 × 10 6 cells per tested condition. After 1 hour of incubation at 4 °C and two subsequent washing steps, cells were incubated with an AlexaFluor 488 labelled, non-competing anti-VP1 antibody (clone 45F07; in-house discoverd) at 1:300 dilution in binding buffer for 20 minutes at 4 °C. After two washing steps, cells were analyzed in analytic flow cytometry. Data was analyzed (n= 1, 15000 cells analyzed per concentration) and figure was prepared using FlowJo 10.7.1. Preparation of BKPyV Pseudoviruses Pseudovirus were produced following instructions described by Buck et al. [ 29 – 35 ] with slight adaptation. In brief, HEK293TT cells [ 36 ] were transfected using a mixture of four plasmids coding for VP1 protein (plasmids pIaw, pII, pIII and PIVc2w encoding VP1 serotype Ia, II, III, and IV, respectively), VP2 protein (ph2b), VP3 Protein (ph3b) and for Luciferase (secNluc). After overnight incubation, media was exchanged and cells were kept at 37 °C, 5 % CO 2 for 2 days. Cells were harvested and washed before they were lysed and virus particles were maturated by sequentially adding 2 U/ml Neuraminidase, 50 mM Tris pH 8, 0.05 % (v/v) Triton X-100 and RNase Cocktail™ Enzyme Mix (1:1000 dilution, Thermo Fisher Scientific). After a final addition of 25 mM ammonium sulfate pH 9 to the cell lysate, final capsid maturation was performed for 23-24 hours at 37 °C. After this overnight incubation, cell lysate was centrifuged and washed and viral particles in the supernatants were kept. After one freeze-thaw cycle of the cell pellet and one additional wash, all supernatants were pooled. Viral particles in the pooled supernatants were purified from free luciferase using gel filtration (2% BCL Agarose Bead Standard (50-150µm), Agarose Beads Technologies). Fractions were tested for presence of infectious viral particle by addition to cells. Only fractions that showed a luciferase signal that could be neutralised by addition of neutralising antibody were pooled. To determine the titer of the generated virus stocks in form of TCID50/ml, virus stocks were serially diluted and each virus dilution tested in six dependant replicates on a 96-well plate. The virus dilution resulting in 50% of infected wells (i.e. luciferase signal above background, i.e. virus without cells) was determined according to Reed & Muench [ 37 ] and TCID50/ml calculated [ 38 ]. Neutralization of BKPyV pseudovirus In 96-well cell culture plates HEK293TT were seeded (20 000 cells/well) and left to adhere for 4.75-7.6 h. Serial 12-point antibody dilutions as well as BKPy pseudovirus (final MOI 0.0358) were prepared in cell medium. Antibody and BKPy pseudovirus were mixed and incubated for 1 h prior addition to the cells in triplicate (except for 24C03 which was done in duplicate). The mix was incubated for 3 days after which the amount of secreted luciferase in the supernatant was determined by the NanoGlo® Luciferase Assay. For this, 40 µl of cell supernatant was transferred to a white, flat bottom 96-well plate and mixed with 40 µl of Nano-Glo® Luciferase Assay Buffer and Substrate mix. After incubation at ambient temperature for 2 min, bioluminescence was analysed using the Tecan Spark plate reader. Numerical readout of luminescence counts/s was done with an integration time of 1000 ms and automatic attenuation mode after 3 s linear shaking with 1 mm amplitude (1440 rpm). This allows for a quantitative analysis of infected cells and the determination of the antibody concentration at which all viral particles could be neutralized (no luciferase release). The percentage of infectivity normalized based on the luciferase readout containing BKPy pseudovirus in the presence (100% infection) or absence (0 %) of cells. Antibody concentrations were transformed (X=Log(X)) and plotted against the normalized signal and the half maximal inhibitory concentrations (IC50) determined using the “log(Inhibitor) vs. normalized response – Variable slope” fitting model of GraphPad Prism 10. Crystallization of 319C07 Fab fragment with VP1 pentamer The crystal structure of BKPyV serotype Ib VP1 pentamer in complex with 319C07 Fab fragments was determined. Fab fragments were generated digesting 319C07 IgG with papain, using Pierce™ Fab Preparation Kit (Thermo Fisher, cat no 44985). For complexation, VP1 was mixed with 319C07 Fab fragment in a 1:1.7 ratio. The complex was separated from non-complexed protein by size exclusion chromatography and concentrated to 26 mg/ml. Crystals were grown by hanging drop vapor diffusion method at 20°C, mixing 0.5 μL of the complex with 0.5 μL of reservoir solution containing 21% (w/v) PEG1500, and 0.1 M MIB buffer pH 4.75. The structure has been deposited in the RCSB Protein Data Bank (Accession# ?TBD). Crystallization was performed by Proteros, Munich, Germany as a commercial service. Long-term co-culture of replication competent BKPyV on human renal proximal tubular epithelial cells and antibody 319C07 The neutralizing efficacy of antibody mAb 319C07 against BK virus (BKPYV) was evaluated using long-term co-cultures with human renal proximal tubular epithelial cells (HRPTEC). HRPTEC were seeded at a density of 3000 cells/well in 96-well plates a day in advance. At assay initiation, medium was refreshed, and antibody dilutions were added at final concentrations ranging from 15 pM to 1.5 nM. BKPyV was introduced at a final dilution of 1:1000. After incubation for one week, viral replication was assessed by qPCR from cell supernatants subjected to viral inactivation by boiling. Cells in remaining supernatant fluid underwent freeze-thaw cycles to release mature viral particles for subsequent infection cycles. Reinfection and antibody treatment occurred every two weeks for a total of five to six cycles. Viral genome copy numbers were quantified via qPCR using a standard curve, and potential viral escape mutants were assessed by sequencing the VP1 gene following the final culture passage. Disclosures MW, SiS, CE, BE, JS, JR, CT, MH and AM, are present or past employees of Memo Therapeutics AG. MW, SiS, CE, TS, UH are inventors on a patent describing mAb 319C07. MW, SiS, CE, BE, JS, JR, CT, MH and AM own options and/or stock of Memo Therapeutics AG. Supplementary information Download figure Open in new tab Figure S1. Binding of BKPyV VP1 serotypes II, III and IV to HEK293TT cells in the presence of mAb 319C07. Attachment of VP1 serotypes II, III and IV pentamer to HEK293TT cells in the absence (dark green) or presence of antibody (mAb319C07, mAb P8D11 or mAb 24C03) at different concentrations (shades of blue) was analyzed. VP1 binding to HEK293TT cells was detected using an AF488 labelled anti-VP1 antibody and compared to cells with detection antibody only (black). Analysis was done by analytic flow cytometry. A shift of the HEK293TT population to higher signals (right-shift) over background (black) indicates binding of VP1 to the cells. View this table: View inline View popup Download powerpoint Table S1. Percent binding of BK VP1 serotype II-IV to HEK293TT cells in the presence or absence of antibodies. Median fluorescent intensity of plots shown were extracted using FlowJo 10.7.1 and normalized to 100 % VP1 binding (VP1 II, III or IV binding to HEK293TT cells in the absence of antibodies) and 0 % VP1 binding (HEK293TT cells with detection antibody only). For mAb 319C07 and mAb P8D11, a concentration-dependent decrease in VP1 binding to the cells was observed. mAb P8D11 shows a weaker inhibition of VP1 binding to cells than mAb 319C07 for all VP1 serotypes tested. mAb 24C03 does not inhibit VP1 binding to HEK293TT cells. n=1, 15000 cells analyzed per concentration. Acknowledgments The authors want to thank the blood donors who donated blood from which the B cell repertoire libraries were made. Flow cytometry was performed at the flow cytometry facility of the University of Zurich. References 1. ↵ Helle , F. ; Brochot , E. ; Handala , L. ; Martin , E. ; Castelain , S. ; Francois , C. ; Duverlie , G. Biology of the BKPyV: An Update . Viruses 2017 , 9 , 327 , doi: 10.3390/v9110327 . OpenUrl CrossRef PubMed 2. ↵ Hurdiss , D.L. ; Frank , M. ; Snowden , J.S. ; Macdonald , A. ; Ranson , N.A. The Structure of an Infectious Human Polyomavirus and Its Interactions with Cellular Receptors . Structure 2018 , 26 , 839 – 847.e3 , doi: 10.1016/j.str.2018.03.019 . OpenUrl CrossRef 3. ↵ Krajewski , W. ; Kamińska , D. ; Janczak , D. Pathogenicity of BK Virus on the Urinary System . Cent. Eur. J. Urol . 2020 , 73 , 94 – 103 , doi: 10.5173/ceju.2020.0034 . OpenUrl CrossRef 4. ↵ Zhou , X. ; Zhu , C. ; Li , H. BK Polyomavirus: Latency, Reactivation, Diseases and Tumorigenesis . Front. Cell. Infect. Microbiol . 2023 , 13 , doi: 10.3389/fcimb.2023.1263983 . OpenUrl CrossRef 5. ↵ Malik , O. ; Saleh , S. ; Suleiman , B. ; Ashqar , B. ; Maibam , A. ; Yaseen , M. ; Elrefaei , A. ; Hines , A. ; Cornea , V. ; El-Husseini , A. ; et al. Prevalence, Risk Factors, Treatment, and Overall Impact of BK Viremia on Kidney Transplantation . Transplant. Proc . 2019 , 51 , 1801 – 1809 , doi: 10.1016/j.transproceed.2019.03.035 . OpenUrl CrossRef PubMed 6. ↵ Kotton , C.N. ; Kamar , N. ; Wojciechowski , D. ; Eder , M. ; Hopfer , H. ; Randhawa , P. ; Sester , M. ; Comoli , P. ; Tedesco Silva , H. ; Knoll , G. ; et al. The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation . Transplantation 2024 , doi: 10.1097/TP.0000000000004976 . OpenUrl CrossRef 7. Bennett , S.M. ; Broekema , N.M. ; Imperiale , M.J. BK Polyomavirus: Emerging Pathogen . Microbes Infect. Inst. Pasteur 2012 , 14 , 672 – 683 , doi: 10.1016/j.micinf.2012.02.002 . OpenUrl CrossRef PubMed 8. ↵ Rinaldo , C.H. ; Tylden , G.D. ; Sharma , B.N. The Human Polyomavirus BK (BKPyV): Virological Background and Clinical Implications . APMIS 2013 , 121 , 728 – 745 , doi: 10.1111/apm.12134 . OpenUrl CrossRef PubMed 9. ↵ Ramos , E. ; Drachenberg , C. ; Wali , R. ; Hirsch , H. The Decade of Polyomavirus BK-Associated Nephropathy: State of Affairs . Transplantation 2009 , 87 , 621 – 630 , doi: 10.1097/TP.0b013e318197c17d . OpenUrl CrossRef PubMed Web of Science 10. ↵ Sawinski , D. ; Forde , K.A. ; Trofe-Clark , J. ; Patel , P. ; Olivera , B. ; Goral , S. ; Bloom , R.D. Persistent BK Viremia Does Not Increase Intermediate-Term Graft Loss but Is Associated with De Novo Donor-Specific Antibodies . J. Am. Soc. Nephrol . 2015 , 26 , 966 – 975 , doi: 10.1681/ASN.2014010119 . OpenUrl Abstract / FREE Full Text 11. ↵ Nankivell , B.J. ; Renthawa , J. ; Sharma , R.N. ; Kable , K. ; O’Connell , P.J. ; Chapman , J.R. BK Virus Nephropathy: Histological Evolution by Sequential Pathology . Am. J. Transplant . 2017 , 17 , 2065 – 2077 , doi: 10.1111/ajt.14292 . OpenUrl CrossRef PubMed 12. ↵ Devresse , A. ; Tinel , C. ; Vermorel , A. ; Snanoudj , R. ; Morin , L. ; Avettand-Fenoel , V. ; Amrouche , L. ; Scemla , A. ; Zuber , J. ; Legendre , C. ; et al. No Clinical Benefit of Rapid versus Gradual Tapering of Immunosuppression to Treat Sustained BK Virus Viremia after Kidney 1. Transplantation: A Single-Center Experience . Transpl. Int. Off. J. Eur. Soc. Organ Transplant . 2019 , 32 , 481 – 492 , doi: 10.1111/tri.13392 . OpenUrl CrossRef 13. ↵ Chandraker , A. ; Regmi , A. ; Gohh , R. ; Sharma , A. ; Woodle , E.S. ; Ansari , M.J. ; Nair , V. ; Chen , L.-X. ; Alhamad , T. ; Norman , S. ; et al. Posoleucel in Kidney Transplant Recipients with BK Viremia: Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial . J. Am. Soc. Nephrol. JASN 2024 , 35 , 618 – 629 , doi: 10.1681/ASN.0000000000000329 . OpenUrl CrossRef PubMed 14. ↵ Hirsch , H.H. ; Randhawa , P.S. ; AST Infectious Diseases Community of Practice BK Polyomavirus in Solid Organ Transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice . Clin. Transplant . 2019 , 33 , e13528 , doi: 10.1111/ctr.13528 . OpenUrl CrossRef PubMed 15. ↵ Naef , B. ; Nilsson , J. ; Wuethrich , R.P. ; Mueller , T.F. ; Schachtner , T. Intravenous Immunoglobulins Do Not Prove Beneficial to Reduce Alloimmunity among Kidney Transplant Recipients with BKV-Associated Nephropathy . Transpl. Int. Off. J. Eur. Soc. Organ Transplant . 2021 , 34 , 1481 – 1493 , doi: 10.1111/tri.13882 . OpenUrl CrossRef 16. ↵ Solis , M. ; Velay , A. ; Porcher , R. ; Domingo-Calap , P. ; Soulier , E. ; Joly , M. ; Meddeb , M. ; KackKack , W. ; Moulin , B. ; Bahram , S. ; et al. Neutralizing Antibody–Mediated Response and Risk of BK Virus–Associated Nephropathy . J. Am. Soc. Nephrol . 2018 , 29 , 326 – 334 , doi: 10.1681/ASN.2017050532 . OpenUrl Abstract / FREE Full Text 17. ↵ Jordan , S.C. ; Limaye , A.P. ; Fischbach , B. ; Sood , P. ; Collette , S. ; Gasink , L.B. ; Patick , A. ; Fordyce , M.W. ; Lin , C.J.F. ; Brennan , D.C. A Randomized Phase 2 Study of MAU868 vs Placebo to Treat BK Viremia in Kidney Transplant Recipients . 15 . 18. ↵ Hillenbrand , M. ; Esslinger , C. ; Seidenberg , J. ; Weber , M. ; Zingg , A. ; Townsend , C. ; Eicher , B. ; Rutkauskaite , J. ; Riese , P. ; Guzman , C.A. ; et al. Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening . 2024 . 19. ↵ NCT05769582 Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients . 20. ↵ Stanley C. Jordan 1, Daniel C. Brennan 2, Amy K. Patick 3, Leanne B. Gasink 3, Celia J. Lin 4, Ajit P. Limaye5 A Randomized Phase 2 Study of MAU868 vs Placebo for BK Viremia in Kidney Transplant Recipients: BK Viral Kinetics and Outcomes in Two Dosing Cohorts . 21. ↵ Durairaj , J. ; Waterhouse , A.M. ; Mets , T. ; Brodiazhenko , T. ; Abdullah , M. ; Studer , G. ; Tauriello , G. ; Akdel , M. ; Andreeva , A. ; Bateman , A. ; et al. Uncovering New Families and Folds in the Natural Protein Universe . Nature 2023 , 622 , 646 – 653 , doi: 10.1038/s41586-023-06622-3 . OpenUrl CrossRef 22. ↵ Neu , U. ; Allen , S.A. ; Blaum , B.S. ; Liu , Y. ; Frank , M. ; Palma , A.S. ; Ströh , L.J. ; Feizi , T. ; Peters , T. ; Atwood , W.J. ; et al. A Structure-Guided Mutation in the Major Capsid Protein Retargets BK Polyomavirus . PLoS Pathog . 2013 , 9 , e1003688 , doi: 10.1371/journal.ppat.1003688 . OpenUrl CrossRef PubMed 23. ↵ Abend , J.R. ; Sathe , A. ; Wrobel , M.B. ; Knapp , M. ; Xu , L. ; Zhao , L. ; Kim , P. ; Desai , S. ; Nguyen , A. ; Leber , X.-C. ; et al. Nonclinical and Clinical Characterization of MAU868, a Novel Human-1. Derived Monoclonal Neutralizing Antibody Targeting BK Polyomavirus VP1 . Am. J. Transplant . 2024 , 24 , 1994 – 2006 , doi: 10.1016/j.ajt.2024.07.002 . OpenUrl CrossRef PubMed 24. ↵ Lindner , J.M. ; Cornacchione , V. ; Sathe , A. ; Be , C. ; Srinivas , H. ; Riquet , E. ; Leber , X.-C. ; Hein , A. ; Wrobel , M.B. ; Scharenberg , M. ; et al. Human Memory B Cells Harbor Diverse Cross-Neutralizing Antibodies against BK and JC Polyomaviruses . Immunity 2019 , 50 , 668 – 676.e5 , doi: 10.1016/j.immuni.2019.02.003 . OpenUrl CrossRef PubMed 25. ↵ Benotmane , I. ; Solis , M. ; Velay , A. ; Cognard , N. ; Olagne , J. ; Gautier Vargas , G. ; Perrin , P. ; Marx , D. ; Soulier , E. ; Gallais , F. ; et al. Intravenous Immunoglobulins as a Preventive Strategy against BK Virus Viremia and BKV-Associated Nephropathy in Kidney Transplant Recipients-Results from a Proof-of-Concept Study . Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg . 2020 , doi: 10.1111/ajt.16233 . OpenUrl CrossRef PubMed 26. ↵ Jordan , S.C. ; Limaye , A. ; Fischbach , B.V. ; Sood , P. ; Collette , S. ; Gasink , L. ; Patick , A. ; Fordyce , M.W. ; Lin , C.J. ; Brennan , D.C. A Randomized Phase 2 Study of MAU868 vs. Placebo to Treat BK Viremia in Kidney Transplant Recipients: SA-OR43 . J. Am. Soc. Nephrol . 2022 , 33 , 46 – 46 , doi: 10.1681/ASN.20223311S146a . OpenUrl CrossRef 27. ↵ Wang , X. ; Stollar , B.D. Human Immunoglobulin Variable Region Gene Analysis by Single Cell RT-PCR . J. Immunol. Methods 2000 , 244 , 217 – 225 , doi: 10.1016/S0022-1759(00)00260-X . OpenUrl CrossRef PubMed Web of Science 28. ↵ Wardemann , H. Predominant Autoantibody Production by Early Human B Cell Precursors . Science 2003 , 301 , 1374 – 1377 , doi: 10.1126/science.1086907 . OpenUrl Abstract / FREE Full Text 29. ↵ Buck , C.B. PseudovirusProduction - CCR Wiki Available online: https://ccrod.cancer.gov/confluence/display/LCOTF/PseudovirusProduction x(accessed on 3 July 2024 ). 30. Buck , C.B. Alternative Protocol: Removal of Capsids Containing Cellular DNA Fragments - CCR Wiki Available online: https://ccrod.cancer.gov/confluence/display/LCOTF/ripcord x(accessed on 3 July 2024 ). 31. Buck , C.B. BKVharvest - CCR Wiki Available online: https://ccrod.cancer.gov/confluence/display/LCOTF/BKVharvest x(accessed on 3 July 2024 ). 32. Buck , C.B. GelFiltration - CCR Wiki Available online: https://ccrod.cancer.gov/confluence/display/LCOTF/GelFiltration x(accessed on 3 July 2024 ). 33. Buck , C.B. ; Cheng , N. ; Thompson , C.D. ; Lowy , D.R. ; Steven , A.C. ; Schiller , J.T. ; Trus , B.L. Arrangement of L2 within the Papillomavirus Capsid . J. Virol . 2008 , 82 , 5190 – 5197 , doi: 10.1128/JVI.02726-07 . OpenUrl Abstract / FREE Full Text 34. Buck , C.B. ; Thompson , C.D. Production of Papillomavirus-Based Gene Transfer Vectors . Curr. Protoc. Cell Biol . 2007 , 37 , 26 .1.1-26.1.19 , doi: 10.1002/0471143030.cb2601s37 . OpenUrl CrossRef 35. ↵ Pastrana , D.V. ; Brennan , D.C. ; Ģuburu , N. ; Storch , G.A. ; Viscidi , R.P. ; Randhawa , P.S. ; Buck , C.B. Neutralization Serotyping of BK Polyomavirus Infection in Kidney Transplant Recipients . PLoS Pathog . 2012 , 8 , e1002650 , doi: 10.1371/journal.ppat.1002650 . OpenUrl CrossRef PubMed 36. ↵ Buck , C.B. ; Pastrana , D.V. ; Lowy , D.R. ; Schiller , J.T. Efficient Intracellular Assembly of Papillomaviral Vectors . J. Virol . 2004 , 78 , 751 – 757 , doi: 10.1128/JVI.78.2.751-757.2004 . OpenUrl Abstract / FREE Full Text 37. ↵ Reed , L.J. ; Muench , H. A Simple Method of Estimating Fifty per Cent Endpoints . Am J Epidemiol 1938 , 27 , 493 – 497 , doi: 10.1093/oxfordjournals.aje.a118408 . OpenUrl CrossRef PubMed 38. ↵ Lei , C. ; Yang , J. ; Hu , J. ; Sun , X. On the Calculation of TCID50 for Quantitation of Virus Infectivity . Virol. Sin . 2021 , 36 , 141 – 144 , doi: 10.1007/s12250-020-00230-5.1 . OpenUrl CrossRef PubMed View the discussion thread. Back to top Previous Next Posted April 19, 2025. Download PDF Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following A Highly Potent Human Antibody Neutralizing All Serotypes of BK Polyomavirus Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share A Highly Potent Human Antibody Neutralizing All Serotypes of BK Polyomavirus Marcel Weber , Simone Schmitt , Barbara Eicher , Jemima Seidenberg , Justina Rutkauskaite , Catherine Townsend , Uyen Huynh-Do , Thomas Schachtner , Serena Delbue , Armin Mäder , Christoph Esslinger , Matthias Hillenbrand bioRxiv 2025.04.14.648680; doi: https://doi.org/10.1101/2025.04.14.648680 Share This Article: Copy Citation Tools A Highly Potent Human Antibody Neutralizing All Serotypes of BK Polyomavirus Marcel Weber , Simone Schmitt , Barbara Eicher , Jemima Seidenberg , Justina Rutkauskaite , Catherine Townsend , Uyen Huynh-Do , Thomas Schachtner , Serena Delbue , Armin Mäder , Christoph Esslinger , Matthias Hillenbrand bioRxiv 2025.04.14.648680; doi: https://doi.org/10.1101/2025.04.14.648680 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Immunology Subject Areas All Articles Animal Behavior and Cognition (7635) Biochemistry (17697) Bioengineering (13895) Bioinformatics (41951) Biophysics (21456) Cancer Biology (18594) Cell Biology (25520) Clinical Trials (138) Developmental Biology (13381) Ecology (19903) Epidemiology (2067) Evolutionary Biology (24323) Genetics (15612) Genomics (22510) Immunology (17738) Microbiology (40401) Molecular Biology (17184) Neuroscience (88622) Paleontology (667) Pathology (2833) Pharmacology and Toxicology (4825) Physiology (7644) Plant Biology (15158) Scientific Communication and Education (2046) Synthetic Biology (4296) Systems Biology (9825) Zoology (2271)